Histrelin is a synthetic GnRH agonist delivered as a subcutaneous implant for continuous drug release. It is studied for its potent ability to suppress sex hormone production, used in conditions like advanced prostate cancer and central precocious puberty.
In the literature, Histrelin appears most often in work focused on hormone support, cancer research and fertility. Studies in this area tend to look at mechanisms and observed effects in laboratory and preclinical settings rather than outcomes in people, so the picture is best read as a map of where researchers have been curious — not as evidence of any benefit.
Histrelin is catalogued here under powder peptides. Coverage of this compound varies in quality and depth, and much of it remains early-stage. Reading the underlying research directly is the only way to judge how strong any particular finding is.
Tap a topic to see which peptides are most studied for it.
Buserelin is a synthetic GnRH agonist analog used clinically for hormone-sensitive conditions. Researchers study its effects on hormone regulation for conditions like prostate cancer, endometriosis, and fertility treatments.
A gonadotropin studied for testicular function, fertility, and hormonal axis research.
Human menopausal gonadotropin, studied in fertility and reproductive hormone research.
Research use only. This page summarizes areas of published study and is not medical advice. No dosing, protocol, or usage guidance is provided.